The announcement indicates a strategic move to optimize operations while ensuring service continuity, which could reassure investors about DermTech's operational stability and future prospects. The one-time charge is significant but expected, and the company's confidence in handling orders for its melanoma test suggests operational efficiency. However, the impact on the stock price is neutral short-term as the market may adopt a wait-and-see approach regarding the outcomes of the strategic review.